Novartis Ag

Enterprise Therapeutics Limited

Orca Pharmaceuticals Limited

Clive McCarthy

Pascal Furet

Ian Bruce

Graham Charles Bloomfield

Catherine LeBlanc

Louise Clare Kirman

Mark G Bock

Robin Alec Fairhurst

Giorgio Caravatti

Heinrich Rueeger

Roger John Taylor

Neil John Press

Joseph Schoepfer

Darren Mark Le Grand

Henrik Moebitz

Chetan Pandit

Guido Bold

Stefan Stutz

Vito Guagnano

Andrea Vaupel

Stephen Paul Collingwood

Jean-Michel Rene Rondeau

Rainer Machauer

Catherine Leblanc

Urs Baettig

Marina Tintelnot-Blomley

Bernard Cuenoud

Siem Jacob Veenstra

Gurdip Bhalay

Ramulu Poddutoori

Naomi Went

Duncan Alexander Hay

Thomas Beauregard Schofield

Jonathan David Hargrave

Judy Fox Hayler

Frédéric Stauffer

Nicolas Soldermann

Thomas Hugo Keller

Mrinalini Sachin Oza

Roine Inge Olsson

Lewis Whitehead

Lyndon Nigel Brown

Dinesh Chikkanna

Nicola Press

Peter Finan

Frank Hans Seiler

Alastair Denholm

Lena Shukla

Manuel Koller

Claudia Betschart

Carsten Spanka

Andrew Dunstan

Kurt Laumen

Andreas Lerchner

Trevor John Howe

Clive Victor Walker

Angela Glen

Gaynor Elizabeth Woodward

Lewis Whithead

John James Woods

Ramulu Poddutorri

Melanie Stang

Compounds of general formula (I) wherein R, R, R, R, Rand X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.

Substituted benzodiazoliums as ENaC inhibitors

The present invention discloses bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives of formula (I) as inhibitors of ENaC and are of use in the treatment of respiratory diseases and conditions, skin conditions or ocular conditions, wherein the respiratory disease or condition is e.g. cystic fibrosis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, including non-cystic fibrosis bronchiectasis, and asthma; the skin condition is e.g. psoriasis, atopic dermatitis and ichthyosis; and the ocular condition is e.g. dry eye disease. 

Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases

The invention relates to compounds of general formula (I): wherein R, R, R, Rand Xare as defined herein. The compounds are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions. 

Compounds

The present invention provides compounds of formula (I), wherein A, A, Z, Z, Z, R, R, R, R, R, R, n, p and q are as defined herein. In certain embodiments, the compounds of the invention are ROR&#x3b3;t antagonists. In other embodiments, the compounds of the invention are useful in the treatment and/or prevention of inflammatory and autoimmune conditions. 

Indazole and indole derivatives as inhibitors of retinoic acid related orphan receptor gamma (ROR gamma) for the treatment of immune-related diseases

The invention relates to compounds of formula (I), wherein Rand Rare as defined herein. The compounds of the invention are inhibitors of ROR&#x3b3;t and are useful in the treatment of diseases and conditions mediated by ROR&#x3b3;t. 

Indolyl-containing ROR&#x3b3;t inhibitors

The present invention relates to compounds of formula (I): wherein Rand Rare as defined herein. In certain embodiments, the compounds of the present invention are inhibitors of ROR&#x3b3;t and are useful in the treatment of diseases and conditions mediated by ROR&#x3b3;t.

The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

Oxazolidin-2-one compounds and uses thereof

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

3-Methyl-imidazo[1,2-b]pyridazine derivatives

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases (e.g., cancer and inflammation). 

Heterocyclic sulfonamide derivatives

The present invention relates to compounds of Formula I where R, R, X, R, R, W, R, R, and Rare as defined herein as well as pharmaceutically acceptable salts thereof. The compounds have been shown to act as MEK inhibitors which may be useful in the treatment of hyperproliferative diseases, like cancer and inflammation.

3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives

Compounds of formula I in free or salt form, wherein R, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

5-phenylthiazole derivatives and use as PI3 kinase inhibitors

The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Macrocyclic compounds useful as BACE inhibitors

Growing community of inventors

Basel, Switzerland

Clive McCarthy